Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended 30 September 2016
Issuance Date: 26 October 2016
GSK reported strong operational performance across its three core businesses: Pharmaceuticals, Vaccines, and Consumer Healthcare. The results reflect the integration of the Novartis Vaccines and Consumer Healthcare businesses acquired in 2015 and the exclusion of the former Oncology business. Management highlighted sustained sales growth, improved cash flow, and significant progress in the R&D pipeline.
Key Financial Metrics
| Metric | Q3 2016 | Q3 2015 | 9M 2016 | 9M 2015 |
|---|---|---|---|---|
| Turnover | £7,542m | £6,127m | £20,303m | £17,637m |
| Core Operating Profit | £2,319m | £1,718m | £5,709m | £4,372m |
| Core Operating Margin | 30.7% | 28.0% | 28.1% | 24.8% |
| Total Operating Profit | £1,431m | £1,025m | £2,003m | £10,576m |
| Core EPS | 32.0p | 23.0p | 76.3p | 57.7p |
| Total EPS | 16.6p | 11.1p | 13.5p | 181.7p |
| Net Cash Inflow from Operations | £1,767m | £481m | £3,506m | £1,068m |
| Free Cash Flow | £1,226m | (£33m) | £1,319m | (£708m) |
| Net Debt | £14,663m | £10,551m | £14,663m | £10,551m |
Material Changes vs. Prior Period
- Revenue Growth: Group turnover increased 8% on a Constant Exchange Rate (CER) basis in Q3 2016, driven by growth in all three segments. New Pharmaceutical and Vaccine product sales grew 79% to £1.21 billion.
- Profitability: Core operating profit margin improved to 30.7% in Q3 2016 (up from 28% in Q3 2015) due to operating leverage, cost savings, and a favorable product mix. Total operating profit for the 9-month period was significantly lower than the prior year (£2,003m vs £10,576m) primarily due to the absence of the one-time gain from the Oncology business disposal in 2015.
- EPS Volatility: While Core EPS grew 12% CER in Q3, Total EPS was down 1% CER. This divergence was caused by significant non-core charges (£799m in Q3) related to the re-measurement of contingent consideration and put option liabilities for the Consumer Healthcare and ViiV Healthcare joint ventures.
- Cash Flow: Net cash inflow from operations improved substantially to £1.8 billion in Q3 compared to £0.5 billion in the prior year, reflecting improved operational performance.
Guidance, Outlook, and Risks
- 2016 Guidance: GSK maintains its expectation for 2016 Core EPS percentage growth of 11-12% on a CER basis. If exchange rates hold at Q3 period-end levels, the estimated positive impact on full-year Sterling Core EPS growth would be approximately 21%.
- Dividends: A quarterly dividend of 19p was declared. The Board expects to pay an annual ordinary dividend of 80p for both 2016 and 2017.
- R&D Pipeline: Significant progress was reported, including the US filing of Shingrix (shingles vaccine) and the filing of Benlysta subcutaneous for lupus. Phase III trials for a two-drug HIV regimen and four other assets are expected to start by year-end.
- Risks and Contingencies:
- Transaction-Related Adjustments: Significant volatility in total results is driven by re-measurements of liabilities for put options and contingent consideration, which are sensitive to exchange rate fluctuations and business performance forecasts.
- Legal Matters: The Group reached a global resolution with the US SEC regarding the Foreign Corrupt Practices Act investigation; the DOJ concluded its investigation with no action. Aggregate legal provisions stood at £0.3 billion.
- Product Lifecycle: Continued decline in sales of Seretide/Advair due to generic competition is factored into future outlooks.
Investor Verification Checklist
- Core vs. Total Results: Verify the reconciliation between Core and Total results, specifically the £799m transaction-related charge in Q3 driven by exchange rate assumptions and liability re-measurements.
- Net Debt Increase: Confirm the drivers of the net debt increase to £14.7 billion, primarily dividends paid (£3.9 billion) and adverse exchange impacts on non-Sterling debt.
- Respiratory Portfolio Transition: Monitor the offset between declining Advair/Seretide sales and the growth of new Ellipta products (Breo, Relvar, Anoro, Incruse) to ensure the transition remains on track.
- FX Sensitivity: Assess the impact of Sterling weakness on future earnings, as the company noted a significant positive currency impact on reported Sterling figures.
- Put Option Liabilities: Review the estimated present value of the Consumer Healthcare and ViiV Healthcare put options, which increased to £7.3 billion and £2.5 billion respectively, and their sensitivity to exchange rates.